Malignant solid tumors (lung cancer, breast cancer, gastrointestinal cancer, ovarian cancer, etc.), antineoplastic drug-related cardiotoxicity (myocardial injury, cardiac dysfunction, arrhythmia, heart failure, etc.)
Conditions
Interventions
Antineoplastic drug treatment group:None
Sponsors
Harbin Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Diagnosed with solid malignant tumors (including lung cancer, breast cancer, gastrointestinal tumors, ovarian cancer, etc.) by pathological histology or cytology, and received anti - tumor drug treatments such as chemotherapy, targeted therapy, and immunotherapy in our hospital from January 2020 to December 2025; 2.The baseline data of cardiac function is complete, and the patient can cooperate to complete cardiac-related examinations such as electrocardiogram and echocardiogram. 3.The clinical data, medication records, and follow - up information are complete, which can meet the requirements for multi - modal data collection and analysis.
Exclusion criteria
Exclusion criteria: 1.Those who have combined severe primary heart diseases (such as refractory heart failure, severe arrhythmia, acute myocardial infarction, etc.) and cannot tolerate anti - tumor treatment. 2.Patients with mental illness or cognitive impairment who are unable to cooperate with the collection and monitoring of research data. 3.Those with severely missing clinical data and unable to be included in the data model analysis;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antineoplastic drug-related cardiotoxicity; | — |
Countries
China
Contacts
Public ContactDong Mei
Harbin Medical University Cancer Hospital
Outcome results
None listed